Business Wire

DOCOMO to Exhibit at World’s Largest Mobile Exhibition: MWC Barcelona 2023

Share

NTT DOCOMO, INC. announced today that it will organize a full-scale booth at MWC Barcelona 2023, the world’s largest mobile-related exhibition, in Barcelona, Spain from February 27 to March 2.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230120005094/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

NTT DOCOMO Booth at MWC Barcelona 2023 (Graphic: Business Wire)

The DOCOMO booth, which will showcase exhibitions and presentations focused on the main themes of 6G, open radio access networks (Open RAN) and extended reality (XR), will also promote international standardization and global business for next-generation communication technologies. Due to the global pandemic, this will be DOCOMO’s the first onsite appearance at MWC Barcelona since 2019.1

In the 6G section, DOCOMO will present the coming 6G world and advanced wireless technologies that the company is currently developing. This will include a demonstration of the Human Augmentation Platform to communicate haptic sensations between people connected to a 6G network to enable, for example, a musical student to mimic the exact finger motions of a teacher.

In the Open RAN section, DOCOMO will present experiential content to help visitors understand the concept and structure of Open RAN, as well as progress being achieved to enable multi-vendor telecommunication equipment2 to be combined in Open RAN, as well as related collaborations with international carriers.

In the XR section, visitors will experience the metaverse filled with music, anime and movies and also a virtual-live system, both provided by NTT QONOQ, INC., a company launched by DOCOMO’s parent NTT group last October to promote XR business.

Through this exhibition, DOCOMO looks forward to globally communicating its advanced technologies and businesses under the company’s brand slogan “changing worlds with you.”

For more about DOCOMO’s exhibits and the overall exhibition, please refer to the appendix.

1 DOCOMO organized an exhibition in Japan in 2021 and then one online in 2022.
2 Creation of 5G Open RAN Ecosystem to Accelerate Adoption of Open RAN by Operators Globally”
https://www.docomo.ne.jp/english/info/media_center/pr/2021/0208_00.html

About NTT DOCOMO

NTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/

Appendix

Overview of NTT DOCOMO Booth at MWC Barcelona 2023

1. Exhibitions

Theme

Exhibits

Contents

6G

Human Augmentation Platform

As an example of this 6G application, presenters will use haptic information to teach musical techniques and guide a robot in whisking green tea.

Wireless Technologies

DOCOMO’s technical approaches to the realization of 6G will be introduced with detailed explanations.

Open RAN

Interactive Contents

Experiential content in the form of a simulation game will allow visitors to grasp the overview and structure of Open RAN.

Shared Open Lab
Virtual Tour

This Open RAN verification facility located at the DOCOMO R&D Center in Japan will be introduced in 3D.

XR

XR World

This metaverse diorama will enable people to view a life-size Godzilla from various angles.

Matrix Stream

Presenting NTT QONOQ’s virtual-live and general-purpose video-delivery system for extended reality

Mixed Reality Animals—Volumetric Video × Magic Leap 2

Videos of real cats and penguins will be converted to 3DCG and projected into real space using a Magic Leap 2 MR headset.

2. NTT DOCOMO Booth Location

4E50, Hall 4

3. Presentations

1

Broadcast Stage
Title: On the Forefront of Open RAN Implementation
When: Monday, February 27 from 15:45 to 16:15 (local time)
Where: Broadcast Studio, Hall 4
Speaker: Mr. Sadayuki Abeta, OREC evangelist, NTT DOCOMO

2

5G Futures Summit
Session 4: Driving Supply Chain Resiliency & Interoperable Networks
When: Wednesday, March 1 from 14:50 to 15:50 (local time)
Where: Theatre 2, Hall 6
Speaker: Mr. Sadayuki Abeta, OREC evangelist, NTT DOCOMO
URL: https://www.mwcbarcelona.com/agenda/session/5g-futures-summit

Note: The content and schedule of the presentations are subject to change. Please check the official website of MWC Barcelona 2023 for the latest information.

Reference

MWC Barcelona 2023

1. Dates & Times
Monday, February 27 to Thursday, March 2
08:30 to 19:00, except last day from 08:30 to 16:00 (all times local)

2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain

3. Official Website
https://www.mwcbarcelona.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:
NTT DOCOMO
Mr. Ryoichi Sakurai or Mr. Yasutaka Imai
Brand Communication Department
Tel: +81 (0)3 5156 1366
Fax: +81 (0)3 5501 3408
Mail: global_pr@nttdocomo.com
www.docomo.ne.jp/english/

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye